Evotec, a Germany-based biotech company, has collaborated with The Global Antibiotic Research and Development Partnership (GARDP) to discover antibiotics intended for the treatment of drug-resistant bacterial infections, it was reported yesterday.

Both parties say that they will strive to address the increasing threat of antimicrobial resistance.

The alliance will integrate The GARDP's clinical expertise and Evotec's drug discovery platform, medicinal chemistry and pharmacology expertise and its range of bacterial pathogens. The collaboration will concentrate on fast tracking the development of antibiotic treatments for hard-to-treat bacterial infections by creating a platform that will cover the length of the drug development value chain. The collaborators will also work on developing a joint pipeline and also claim to ensure that any discovered antibiotics are priced sensibly and are globally available to all patients who require them.